Monoclonal antibodies in the treatment of bronchial asthma

Ilina, N I; Курбачева, О М

doi:10.36691/rja145

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В исследованиях начала XX века, посвящённых изучению особенностей патогенеза бронхиальной астмы (БА), описывались данные, которые позволяли говорить о разнообразии механизмов развития болезни [1,2]. В последующем это привело к выделению не только фенотипов, но и эндотипов БА -T2-опосредованное эозинофильное воспаление и не-Т2-опосредованное нейтрофильное (неэозинофильное) воспаление, которые имеют различные факторы риска и механизмы воспаления, от чего в свою очередь зависит терапия заболевания [3,4].…”

Section: Introductionunclassified

Dupilumab: new opportunities for the treatment of asthma and chronic rhinosinusitis with nasal polyps

Dyneva

Есенгельдыевна²,

Aminova

et al. 2021

Russian Journal of Allergy

View full text Add to dashboard Cite

Airway inflammation plays a key role in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The inflammatory process can vary in intensity thus affecting the clinical picture of the disease and, most importantly, the effectiveness of therapy. Today, there is still a high rate of growth in the incidence of asthma and CRSwNP and dissatisfaction with the effectiveness of existing therapy for severe forms of asthma, especially when asthma is associated with CRSwNP, so the main task is to find new approaches to diagnosis and therapy. The development of biologics is a promising step forward in achieving control of severe and poorly controlled asthma and recurrent CRSwNP that target individual and specific components of inflammation. One of the latest monoclonal antibodies is Dupilumab that has shown significant success in the treatment of asthma and CRSwNP. Dupilumab is a fully human monoclonal antibody directed against the subunit of the Il-4 interleukin receptor (IL-4ra), common to both IL-4 and IL-4/IL-13 receptor complexes. This contributes to the suppression of type 2 cytokine signaling (IL-4 and IL-13), since the IL-4/IL-13/STAT6 signaling pathway plays a crucial role in type 2- inflammation. Currently, Dupilumab is approved for the treatment of severe asthma and CRSwNP, so this article summarizes the main information about Dupilumab and its effectiveness in these diseases, as well as presents the results of clinical observation.

show abstract

Section: Introductionunclassified

Dupilumab: new opportunities for the treatment of asthma and chronic rhinosinusitis with nasal polyps

Dyneva

Есенгельдыевна²,

Aminova

et al. 2021

Russian Journal of Allergy

View full text Add to dashboard Cite

show abstract

Dupilumab: basic aspects and applications to T2-mediated diseases

2021

View full text Add to dashboard Cite

The asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), atopic dermatitis (AD), eosinophilic esophagitis and other diseases based on T2-inflammation are a widespread in the world. It has led to the development of genetically engineered drugs aimed at individual and specific components of inflammation. One of the leading positions in the pathogenesis of T2-mediated diseases is occupied by interleukin (IL)-4 and IL-13, which explains the prospects of studying these cytokines for the creation of anti-IL-4/IL-13 monoclonal antibodies. The first immunobiological drug was registered to directe against the α subunit of the IL-4 receptor (IL-4Ra), common to both IL-4 and IL-4/IL-13 receptor complexes is dupilumab which is a fully human monoclonal antibody. Dupilumab targets the IL-4 receptor alpha chain (IL-4Rα), common to both IL-4R complexes: type 1 (IL-4Rα/γc; IL-4 specific) and type 2 (IL-4Rα/IL-13Rα1; IL-4 and IL-13 specific). Because the IL-4/IL-13/STAT6 signaling pathway plays a significant role in T2 inflammation. IL-4 and IL-13 are secreted by several cells and, along with other T2 cytokines, as well as with the participation of IL-33, IL-25 and TSLP can stimulate cells to further secrete pro-inflammatory cytokines, contributing to the maintenance of the inflammatory process. Currently, dupilumab has been studied in at least 3,000 patients with asthma, AD, CRSwNP and eosinophilic esophagitis. The results of investigation show an acceptable safety profile in placebo-controlled studies worldwide. In this article, we have highlighted the results of numerous clinical studies and observations that have proven the effectiveness and safety of the use of dupilumab in asthma, AD, CRSwNP, prurigo, eosinophilic esophagitis and eosinophilic pneumonia.

show abstract

Case report of the dupilumab applying in atopic dermatitis child

Revyakina

Revyakina²,

Ларькова

et al. 2021

Russian Journal of Allergy

View full text Add to dashboard Cite

In recent years, there has been a clear trend towards an increase in the number of patients with severe atopic dermatitis. In most cases, patients are dissatisfied with the previous therapy, which requires hospital treatment to relieve acute manifestations of atopic dermatitis and the selection of pharmacological agents aimed at achieving long-term control under the of the disease symptoms The article presents the features of the atopic dermatitis therapy of at the present stage, the experience of using the new biological drug dupilumab in a 7-year-old child.

show abstract

Monoclonal antibodies in the treatment of bronchial asthma

Cited by 3 publications

References 0 publications

Dupilumab: new opportunities for the treatment of asthma and chronic rhinosinusitis with nasal polyps

Dupilumab: new opportunities for the treatment of asthma and chronic rhinosinusitis with nasal polyps

Dupilumab: basic aspects and applications to T2-mediated diseases

Case report of the dupilumab applying in atopic dermatitis child

Contact Info

Product

Resources

About